Shin Nippon Biomedical Laboratories Release: Novel Nasal Epinephrine Shows Comparable Absorption to EpiPen® in a Feasibility Study
Published: Sep 10, 2013
SAN FRANCISCO, Sept. 10, 2013 (GLOBE NEWSWIRE) -- Shin Nippon Biomedical Laboratories, Ltd. ('SNBL' Chairman and CEO, Ryoichi Nagata MD PhD FFPM, Tokyo, Japan) and G2B Pharma Inc. ('G2B' Chairman and CEO, Nigel Ten Fleming PhD, San Francisco, USA) announce the completion of a preclinical feasibility study investigating a nasally-delivered epinephrine (adrenaline) formulation for treating anaphylaxis. The study demonstrated that this needle-free nasal epinephrine formulation succeeded in achieving rapid absorption in peripheral blood comparable to EpiPen®, the leading injectable product.
Help employers find you! Check out all the jobs and post your resume.